ROS1 and non-small cell lung carcinoma: In contrast, in the ALK and ROS1 fusion-negative specimens, the OFA sNGS panel identified NSCLC-relevant SNVs and indels in nearly 80% (293/368) of cases, indicating that at least one oncogenic or likely oncogenic variant or a variant of uncertain significance (VUS) was identified.